BioXcel Therapeutics is trading 22.13% down at $0.09 after continued pressure from its August 27, 2026 Chapter 11 filing and Nasdaq’s August 31 delisting decision.
- Nasdaq plans to suspend trading on September 8, 2026; shares are expected to move to the OTC Pink Limited Market.
- The delisting threatens liquidity and investor access while bankruptcy proceedings continue.
- Broader markets are nearly flat, making macro sentiment secondary.